Skip to main content
SP5007,798.99+0.65%DOW53,839.99+0.13%NASDAQ26,803.03+0.81%BTC$63,483.00-0.06%ETH$1,886.42+0.31%GOLD$4,396.70-0.54%OIL$81.15-0.12%
Smart Investors Daily
Sign InSign Up Free
HU

NASDAQ · HURA

TuHURA Biosciences, Inc.

Healthcare · Biotechnology

$2.30

Down-$0.04 (-1.71%)

Updated Aug 14, 2026, 2:09 AM

SID Score

4.0/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
52.85M
P/E ratio
-0.79
Dividend yield
0.00%
52-week range
$0.41 – $3.90
Volume
522.28K
Avg. volume
236.59K

Price performance

HURA price history

1M range · 21 trading sessions · Daily adjusted prices

HURA closed at $2.30 after 21 trading sessions, up 3.60% for the selected period.

Last close
$2.30
Period change
+3.60%
Period low
$2.04
Period high
$2.34
Daily close
View OHLC price history
HURA OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Aug 13, 2026$2.40$2.58$2.29$2.30522.28K
Aug 12, 2026$2.31$2.52$2.28$2.34646.5K
Aug 11, 2026$2.17$2.40$2.115$2.30676.92K
Aug 10, 2026$2.15$2.22$2.12$2.15183.51K
Aug 7, 2026$2.15$2.15$2.08$2.1366.82K
Aug 6, 2026$2.08$2.15$2.07$2.11588.21K
Aug 5, 2026$2.13$2.14$2.04$2.09132.93K
Aug 4, 2026$2.15$2.18$2.083$2.09199.63K
Aug 3, 2026$2.20$2.22$2.12$2.14208.02K
Jul 31, 2026$2.17$2.17$2.0711$2.17143.15K
Jul 30, 2026$2.11$2.175$2.085$2.17258.56K
Jul 29, 2026$2.13$2.14$1.995$2.04236.4K
Jul 28, 2026$2.21$2.24$2.07$2.13213.86K
Jul 27, 2026$2.16$2.24$2.1449$2.21124.07K
Jul 24, 2026$2.17$2.205$2.10$2.11204.19K
Jul 23, 2026$2.20$2.245$2.13$2.15167.15K
Jul 22, 2026$2.24$2.265$2.20$2.24139.04K
Jul 21, 2026$2.27$2.30$2.21$2.21154.15K
Jul 20, 2026$2.23$2.26$2.205$2.24181.66K
Jul 17, 2026$2.17$2.28$2.17$2.25162.49K
Jul 16, 2026$2.28$2.30$2.15$2.22491.56K

Latest HURA news

The latest Smart Investors Daily articles mentioning HURA.

Stock researchCompany · Overview

HURA research

Overview

Company profile and research snapshot.

Company profile

TuHURA Biosciences Inc is a Phase 3 registration stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. The company's personalized cancer vaccine candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors. It is preparing to initiate a single randomized placebo-controlled Phase 3 registration trial of IFx-2.0 administered as an adjunctive therapy to Keytruda (pembrolizumab) in first-line treatment for advanced or metastatic Merkel Cell Carcinoma.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
—
Implied upside
—
Analysts
—
HURA recent ratings
DateFirmRatingTarget
Apr 27, 2026CitizensMarket Outperform—
Feb 3, 2026HC Wainwright & Co.Buy—
Jan 9, 2026HC Wainwright & Co.Buy—
Nov 14, 2025Maxim GroupBuy—
May 16, 2025HC Wainwright & Co.Buy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Jun 15, 2026

TuHURA Biosciences Files Investigational New Drug Application for Evaluation of the TBS-2025 VISTA Inhibiting Antibody in Molecularly Defined Subsets of AML and Other Blood Related Cancers

TuHURA Biosciences, Inc. (NASDAQ: HURA) ("TuHURA" or the "Company"), a Phase 3 immuno-oncology company developing novel therapeutics to overcome resistance to cancer immunotherapy, today announced that it has filed an Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA) for the study of its TBS-2025 VISTA inhibiting antibody for the treatment of molecularly defined subsets of AML and other blood related cancers. The IND is being filed following detailed fee

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By